US · KURA · BIOTECHNOLOGY
Kura Oncology, Inc. (KURA) intrinsic value and stock valuation
$6.91as of 2026-11-21 · Mkt cap 816.72M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Kura Oncology, Inc. DCF and intrinsic value
InvestorsCraft values KURA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from KURA’s statements →
Kura Oncology, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Tango Therapeutics, Inc. (TNGX) $21.73
- Tyra Biosciences, Inc. (TYRA) $20.12
- Bicara Therapeutics Inc. Common Stock (BCAX) $8.44
- Savara Inc. (SVRA) $4.26
- EyePoint Pharmaceuticals, Inc. (EYPT) $0.23
- Replimune Group, Inc. (REPL) $19.07
- Maravai LifeSciences Holdings, Inc. (MRVI) $6.98
- Prime Medicine, Inc. (PRME) $3.55
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0.00 | $0.00 | $0.00 |
| Operating income | -$-303.63M | -$-193.19M | -$-165.8M | -$-139.87M | -$-131.26M |
| Net income | -$-278.67M | -$-173.98M | -$-152.63M | -$-135.84M | -$-130.47M |
| EPSd | -$-3.18M | -$-2.02M | -$-2.08M | -$-2.03M | -$-1.97M |
| Operating cash flow | -$-64.06M | $134.3M | -$-124.82M | -$-110.06M | -$-104.55M |
| Capital expenditure | -$-6.64M | -$-470K | -$-170K | -$-630K | -$-1.15M |
| Free cash flow | -$-70.7M | $133.8M | -$-124.99M | -$-110.69M | -$-105.7M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Total debt | $20.5M | $16.6M | $17.2M | $14M | $6.88M |
| Net debt | -$-128.64M | -$-207.87M | -$-20.12M | -$-37.78M | -$-83.8M |
| Total equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M |
| Cash and short-term investments | $667.2M | $727.4M | $424M | $438M | $518M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $60K | $0.00 | $850K | $0.00 | $0.00 |
| Gross profit | $67.4M | $53.9M | -$-850K | $0.00 | $0.00 |
| Research and development expenses | $251.1M | $170M | $115.2M | $92.8M | $84.7M |
| Selling, general and administrative expenses | $120M | $77.1M | $50.6M | $47.1M | $46.5M |
| Other expenses | $0.00 | $0.00 | -$-850K | $0.00 | $0.00 |
| Operating expenses | $371.1M | $247.1M | $165M | $139.9M | $131.3M |
| Cost and expenses | $371.1M | $247.1M | $165.8M | $139.9M | $131.3M |
| Interest income | $26.8M | $22.9M | $14.7M | $4.25M | $1.21M |
| Interest expense | $1.51M | $1.62M | $1.55M | $230K | $410K |
| Depreciation and amortization | $1.03M | $850K | $850K | $760K | $560K |
| Ebitda | -$-275.82M | -$-169.5M | -$-150.23M | -$-134.85M | -$-129.49M |
| Operating income | -$-303.63M | -$-193.19M | -$-165.8M | -$-139.87M | -$-131.26M |
| Total other income/expenses, net | $25.3M | $21.2M | $13.2M | $4.03M | $790K |
| Income before tax | -$-278.37M | -$-171.97M | -$-152.63M | -$-135.84M | -$-130.47M |
| Income tax expense | $300K | $2.02M | $0.00 | $0.00 | $0.00 |
| Net income | -$-278.67M | -$-173.98M | -$-152.63M | -$-135.84M | -$-130.47M |
| Weighted average shares outstanding | $87.7M | $86.2M | $73.2M | $67M | $66.4M |
| Weighted average diluted shares outstanding | $87.7M | $86.2M | $73.2M | $67M | $66.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $667.2M | $727.4M | $424M | $438M | $518M |
| Net receivables | $12.6M | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $410K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $708.7M | $744.8M | $432.5M | $446.4M | $522.3M |
| Property, plant and equipment, net | $15.2M | $7.49M | $8.85M | $6.38M | $8.25M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $29.7M | $15.3M | $16.5M | $9.88M | $11.8M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M |
| Accounts payable | $5.02M | $1.47M | $2.3M | $1.53M | $3.24M |
| Short-term debt | $1.28M | $4.49M | $1.51M | $2.32M | $2.26M |
| Deferred revenue | $49M | $24.3M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $117M | $78.7M | $35.3M | $24.1M | $22.5M |
| Long-term debt | $19.2M | $12.1M | $15.7M | $11.7M | $4.61M |
| Deferred revenue, non-current | $424.9M | $253.9M | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $447.3M | $267.8M | $16.4M | $12M | $4.99M |
| Capital lease obligations | $10.8M | $7.07M | $7.87M | $4.87M | $6.88M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36M | $27.4M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-1.17B | -$-895.42M | -$-721.44M | -$-568.81M | -$-432.97M |
| Accumulated other comprehensive income (loss) | $1.02M | $760K | -$-1.27M | -$-8.03M | -$-1.79M |
| Total equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M |
| Total investments | $518.1M | $502.9M | $386.6M | $386.2M | $427.3M |
| Total debt | $20.5M | $16.6M | $17.2M | $14M | $6.88M |
| Net debt | -$-128.64M | -$-207.87M | -$-20.12M | -$-37.78M | -$-83.8M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-278.67M | -$-173.98M | -$-152.63M | -$-135.84M | -$-130.47M |
| Depreciation and amortization | -$-7.46M | $850K | $850K | $760K | $560K |
| Stock-based compensation | $37.1M | $33.9M | $28.1M | $26.3M | $23.6M |
| Change in working capital | $184.4M | $286.2M | $7.82M | -$-2.98M | -$-3.22M |
| Accounts receivable | -$-6.74M | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | -$-410K | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $4.5M | $15.2M | $10.3M | -$-800K | -$-2.52M |
| Net cash provided by operating activities | -$-64.06M | $134.3M | -$-124.82M | -$-110.06M | -$-104.55M |
| Investments in property, plant and equipment | -$-6.64M | -$-470K | -$-170K | -$-630K | -$-1.15M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-30K | $130K |
| Net cash used for investing activities | -$-13.1M | -$-101.59M | $15.6M | $32.6M | -$-126.83M |
| Common stock issued | $1.79M | $145.8M | $93.6M | $24.7M | $4.43M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $1.79M | $154.4M | $94.8M | $38.6M | -$-3.44M |
| Net change in cash | -$-75.36M | $187.1M | -$-14.48M | -$-38.87M | -$-234.82M |
| Cash at end of period | $149.1M | $224.5M | $37.3M | $52M | $90.9M |
| Operating cash flow | -$-64.06M | $134.3M | -$-124.82M | -$-110.06M | -$-104.55M |
| Capital expenditure | -$-6.64M | -$-470K | -$-170K | -$-630K | -$-1.15M |
| Free cash flow | -$-70.7M | $133.8M | -$-124.99M | -$-110.69M | -$-105.7M |
Line items
Line items
Line items
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- CEO
- Troy Wilson
- Employees
- 260
- Beta
- 0.35
Explore
Frequently asked questions
What is the intrinsic value of Kura Oncology, Inc. (KURA)?
Kura Oncology, Inc. (KURA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is KURA undervalued?
KURA trades at a price of $6.91 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.